HuGE Literature Finder
Records 1-30
|
FOLFIRINOX in advanced pancreatic cancer patients with the double-variant type of UGT1A1 *28 and *6 polymorphism: a multicenter, retrospective study.
Cancer chemotherapy and pharmacology 2021 Jan . Umemoto Kumiko, Takahashi Hideaki, Morizane Chigusa, Yamada Ikuhiro, Shimizu Satoshi, Shioji Kazuhiko, Yoshida Yukio, Motoya Masayo, Mizuno Nobumasa, Kojima Yasushi, Terashima Takeshi, Uesugi Kazuhiro, Ueno Makoto, Furuse Junji, Akimoto Tetsuo, Ikeda Masafu |
|
Association of UGT1A1*6 polymorphism with irinotecan-based chemotherapy reaction in colorectal cancer patients: a systematic review and a meta-analysis.
Bioscience reports 2020 Sep . Zhu Xiaoyun, Ma Ruchao, Ma Xin, Yang Ga |
|
Effect of drug metabolizing enzymes and transporters in Thai colorectal cancer patients treated with irinotecan-based chemotherapy.
Scientific reports 2020 Aug 10 (1): 13486. Atasilp Chalirmporn, Chansriwong Phichai, Sirachainan Ekaphop, Reungwetwattana Thanyanan, Sirilerttrakul Suwannee, Chamnanphon Monpat, Puangpetch Apichaya, Sukasem Chonlaph |
|
Pharmacokinetic and Pharmacogenetic Study of Etoposide in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors.
Pharmaceutical research 2020 Jul 37 (7): 147. Moeung Sotheara, Chevreau Christine, Marsili Sabrina, Massart Christophe, Fléchon Aude, Delva Rémy, Gravis Gwenaëlle, Lotz Jean-Pierre, Bay Jacques-Olivier, Gross-Goupil Marine, Filleron Thomas, Delmas Caroline, Lafont Thierry, Chatelut Etienne, Thomas Fabien |
|
Correlation between UGT1A1 gene polymorphism and irinotecan chemotherapy in metastatic colorectal cancer: a study from Guangxi Zhuang.
BMC gastroenterology 2020 Apr 20 (1): 96. Chen Shaojun, Hua Li, Feng Chengjun, Mo Qia, Wei Mengzhuan, Shen Yongqi, Lin Zhan, Li Guisheng, Xu Junyi, Guo Chengxian, Huang Haix |
|
UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy.
Leukemia 2020 Mar . Díaz-Santa Johana, Rodríguez-Romanos Rocío, Osca Gemma, Pratcorona Marta, Garrido Ana, Coll Rosa, Moret Carla, Escoda Lourdes, Tormo Mar, Heras Inma, Arnan Montse, Vives Susanna, Salamero Olga, Lloveras Natàlia, Bargay Joan, Sampol Antònia, Cruz David, Garcia Antoni, Quiñones Teresa, Esteve Jordi, Sierra Jorge, Gallardo David, |
|
Influence of UGT1A1 polymorphism on etoposide plus platinum-induced neutropenia in Japanese patients with small-cell lung cancer.
International journal of clinical oncology 2019 Mar 24 (3): 256-261. Negoro Yutaka, Yano Ryoichi, Yoshimura Mari, Suehiro Yoko, Yamashita Shinji, Kodawara Takaaki, Watanabe Kyohei, Tsukamoto Hitoshi, Nakamura Toshiaki, Kadowaki Maiko, Morikawa Miwa, Umeda Yukihiro, Anzai Masaki, Ishizuka Tamotsu, Goto Nobuyu |
|
A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies.
Cancer 2019 Jan . Sharma Manish R, Joshi Smita S, Karrison Theodore G, Allen Kenisha, Suh Grace, Marsh Robert, Kozloff Mark F, Polite Blase N, Catenacci Daniel V T, Kindler Hedy |
|
Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
Cancer chemotherapy and pharmacology 2019 Jan 83 (1): 123-129. Fujii Hironori, Yamada Yunami, Watanabe Daichi, Matsuhashi Nobuhisa, Takahashi Takao, Yoshida Kazuhiro, Suzuki Ak |
|
Pharmacogenetic clinical randomised phase II trial to evaluate the efficacy and safety of FOLFIRI with high-dose irinotecan (HD-FOLFIRI) in metastatic colorectal cancer patients according to their UGT1A 1 genotype.
British journal of cancer 2019 Jan 120 (2): 190-195. Páez David, Tobeña María, Fernández-Plana Julen, Sebio Ana, Virgili Anna C, Cirera Lluís, Barnadas Agustí, Riera Pau, Sullivan Ivana, Salazar Julia |
|
Clinical and pharmacogenetic determinants of 5-fluorouracyl/leucovorin/irinotecan toxicity: Results of the PETACC-3 trial.
European journal of cancer (Oxford, England : 1990) 2018 Jun 99 66-77. Tejpar Sabine, Yan Pu, Piessevaux Hubert, Dietrich Daniel, Brauchli Peter, Klingbiel Dirk, Fiocca Roberto, Delorenzi Mauro, Bosman Fred, Roth Arnaud |
|
UGT1A1*6 and UGT1A1*28 polymorphisms are correlated with irinotecan-induced toxicity: A meta-analysis.
Asia-Pacific journal of clinical oncology 2018 Jun . Yang Yuwei, Zhou MengMeng, Hu Mingjun, Cui Yanjie, Zhong Qi, Liang Ling, Huang F |
|
Relevance of CYP3A4*20, UGT1A1*37 and UGT1A1*28 variants in irinotecan-induced severe toxicity.
British journal of clinical pharmacology 2018 Mar . Riera P, Salazar J, Virgili A, Tobeña M, Sebio A, Gallano P, Barnadas A, Páez |
|
A Multicenter Clinical Phase II Study of FOLFOXIRI Plus Bevacizumab as First-line Therapy in Patients With Metastatic Colorectal Cancer: QUATTRO Study.
Clinical colorectal cancer 2018 Feb . Oki Eiji, Kato Takeshi, Bando Hideaki, Yoshino Takayuki, Muro Kei, Taniguchi Hiroya, Kagawa Yoshinori, Yamazaki Kentaro, Yamaguchi Tatsuro, Tsuji Akihito, Iwamoto Shigeyoshi, Nakayama Goro, Emi Yasunori, Touyama Tetsuo, Nakamura Masato, Kotaka Masahito, Sakisaka Hideki, Yamanaka Takeharu, Kanazawa Akiyos |
|
Association of nephrotoxicity during platinum-etoposide doublet therapy with UGT1A1 polymorphisms in small cell lung cancer patients.
Lung cancer (Amsterdam, Netherlands) 2018 12 126 156-161. Anai Satoshi, Iwama Eiji, Yoneshima Yasuto, Otsubo Kohei, Tanaka Kentaro, Nakanishi Yoichi, Okamoto Isa |
|
Distribution of uridine diphosphate glucuronosyltransferase 1A polymorphisms and their role in irinotecan-induced toxicity in patients with cancer.
Oncology letters 2017 Nov 14 (5): 5743-5752. Wang Yang, Yi Cuihua, Wang Yawei, Li Hui, Li Bei, Wang Dan, Du Jintong, Liu Lian, Wang Xiuw |
|
A prospective study of XELIRI plus bevacizumab as a first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
International journal of clinical oncology 2017 Oct 22 (5): 913-920. Ando Koji, Emi Yasunori, Suenaga Toyokuni, Hamanoue Masahiro, Maekawa Soichiro, Sakamoto Yasuo, Kai Seiichiro, Satake Hironaga, Shimose Takayuki, Shimokawa Mototsugu, Saeki Hiroshi, Oki Eiji, Sakai Kenji, Akagi Yoshito, Baba Hideo, Maehara Yoshihiko, |
|
UGT1A1 Gene Polymorphism Predicts Irinotecan-Induced Severe Neutropenia and Diarrhea in Chinese Cancer Patients.
Clinical laboratory 2017 Sep 63 (9): 1339-1346. Peng Hongwei, Duan Zhouping, Pan Decheng, Wen Jinhua, Wei Xiaoh |
|
Examination of multiple UGT1A and DPYD polymorphisms has limited ability to predict the toxicity and efficacy of metastatic colorectal cancer treated with irinotecan-based chemotherapy: a retrospective analysis.
BMC cancer 2017 Jun 17 (1): 437. Liu Dan, Li Jian, Gao Jing, Li Yanyan, Yang Rui, Shen L |
|
UGT1A1 polymorphisms with irinotecan-induced toxicities and treatment outcome in Asians with Lung Cancer: a meta-analysis.
Cancer chemotherapy and pharmacology 2017 Jun 79 (6): 1109-1117. Chen Xuewei, Liu Liping, Guo Zhihua, Liang Wenhua, He Jiaxi, Huang Liyan, Deng Qiuhua, Tang Hailing, Pan Hui, Guo Minzhang, Liu Yang, He Qihua, He Jianxi |
|
UGT1A1*6 polymorphisms are correlated with irinotecan-induced neutropenia: a systematic review and meta-analysis.
Cancer chemotherapy and pharmacology 2017 Jun . Zhang Xue, Yin Jia-Fu, Zhang Jiao, Kong Shu-Jia, Zhang Hong-Yin, Chen Xue-M |
|
A multicenter phase II study of personalized FOLFIRI-cetuximab for safe dose intensification.
Seminars in oncology 2017 Feb 44 (1): 24-33. Boisdron-Celle Michèle, Metges Jean Philippe, Capitain Olivier, Adenis Antoine, Raoul Jean Luc, Lecomte Thierry, Lam You Heng, Faroux Roger, Masliah Claude, Poirier Anne Lise, Berger Virginie, Morel Alain, Gamelin Eri |
|
Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer.
The oncologist 2017 Feb . Kim Ji-Won, Lee Keun-Wook, Kim Kyu-Pyo, Lee Ju Hyun, Hong Yong Sang, Kim Jeong-Eun, Kim Sun Young, Park Sook Ryun, Nam Byung-Ho, Cho Sang-Hee, Chung Ik-Joo, Park Young Suk, Oh Ho-Suk, Lee Myung-Ah, Kang Hye Jin, Park Young Iee, Song Eun-Kee, Han Hye Sook, Lee Kyu Taeg, Shin Dong Bok, Kang Jung Hun, Zang Dae Young, Kim Jee Hyun, Kim Tae W |
|
Effects of Shengjiangxiexin decoction on irinotecan-induced toxicity in patients with UGT1A1*28 and UGT1A1*6 polymorphisms.
Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan 2017 02 37 (1): 35-42. Deng Bo, Jia Liqun, Tan Huangying, Lou Yanni, Li Xue, Li Yuan, Yu Li |
|
Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy.
Journal of Cancer 2017 8 (4): 691-703. Liu Xing-Han, Lu Jun, Duan Wei, Dai Zhi-Ming, Wang Meng, Lin Shuai, Yang Peng-Tao, Tian Tian, Liu Kang, Zhu Yu-Yao, Zheng Yi, Sheng Qian-Wen, Dai Zhi-J |
|
Relationship between UGT1A1*6/*28 gene polymorphisms and the efficacy and toxicity of irinotecan-based chemotherapy.
OncoTargets and therapy 2017 10 3071-3081. Bai Yu, Wu Hai-Wei, Ma Xu, Liu Ying, Zhang Yan-H |
|
An independent, external validation study of proposed genetic biomarkers of irinotecan toxicity and pharmacokinetics.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e14022. Innocenti F, Rosner G L, Qiao W, de Graan A M, Ratain M J, van Schaik R H N, Ramirez J, Mathijssen |
|
Multivariate analysis of pharmacokinetics (PK) and pharmacogenetics (PG) factors following irinotecan (CPT) treatment and the risk of developing neutropenia or diarrhea.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e13052. Valenzuela B, Rebollo J, Escudero V, Martinez-Navarro E, Gonzalez |
|
UGT1A1*28 genotype-driven phase II study of irinotecan and doxifluridine (5'-DFUR, an intermediate form of capecitabine) for metastatic colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011 May 29 (15_suppl): e14074. Kanekiyo S, Hazama S, Shimizu R, Ozasa H, Yamamoto T, Yoshino S, Okayama N, Hinoda Y, Oka |
|
Role of UGT1A1, MTHFR AND TS gene polymorphisms in the prediction of irinotecan (CPT11) and raltitrexed (TOM) gastrointestinal toxicity in pre-treated patients (pts) with metastatic colorectal cancer (CRC).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004 Jul 22 (14_suppl): 2064. Massacesi C, Terrazzino S, Marcucci F, Rocchi M B L, Cappelletti C, Giustini L, Lombardo M, Rinaldi L, Mattioli R, Bonsignori |
- Page last reviewed:Oct 1, 2020
- Page last updated:Jan 19, 2021
- Content source: